Summary

Other Scenarios:

Buyer: Barr Pharmaceuticals, Inc. (BRL) Last Price: 49.75 Market Cap.: 5.46B
Target: Dendreon Corporation (DNDN) Last Price: 19.39 Market Cap.: 1.61B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 873
Biopharmaceuticals 335
Medical Devices   245

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 155)
  • Hydroxyzine Pamoate
  • Pliva Cyproheptadine HCl
  • Pliva Ketorolac Tromethamine
  • Diphenhydramine Hydrochloride
Target (Total: 9)
  • rNAPc2 (Recombinant Nematode Anticoagulant Protein c2)
  • Provenge (Sipuleucel-T)
  • Neuvenge (Lapuleucel-T)
  • Serine Protease Inhibitors
Buyer
  • ViaSpan (Belzer UW)
  • ParaGard T 380A
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 3)
  • Mack-Cali Realty Corp. (CLI)
  • Indevus Pharmaceuticals (IDEV)
  • Common Sense Ltd.
Target (Total: 1)
  • Akzo Nobel N.V. (ADR) (AKZOY)
Buyer (Total: 7)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corp. (ABC)
  • Walgreen Company (WAG)
Target (Total: 2)
  • Genentech, Inc. (DNA)
  • Amgen, Inc. (AMGN)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 8,500 232
Revenue Per Employee 275,594.1 1,499.8
Total Revenue 584.0 0.1
Total Expenses 912.0 24.0
Other Revenue 47.4 0.0
Cost of Revenue 285.8 0.0
SG&A Expense 178.0 6.9
Research & Development 67.5 17.1
Other Operating Expense 0.0 0.0
Operating Income -328.0 -23.9
Unusual Income 380.7 0.0
LT Debt to Capital 56.94 11.93
Fwd P/E 16.34 -16.21
Fwd P/Rev 2.14 325.29
Book Value 1,465.2 125.7
Curr Portion of LTD/Cap Lease 742.4 6.7

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.

Target

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that harness the immune system to fight cancer. Dendreon?s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer. On August 24, 2006, the Company submitted the clinical and non-clinical sections of its biologics license application (BLA) and on November 9, 2006, the Company submitted the chemistry, manufacturing and controls (CMC) section, completing its submission of its BLA to the United States Food and Drug Administration (FDA) for Provenge. On January 12, 2007, the FDA accepted the Company?s BLA filing and assigned Priority Review status for Provenge.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 63.56 100
Operating Margin % 0.07 -35,661.54
Quick Ratio 1.25 5.21
Current Ratio 1.72 5.39
Coverage Ratio -5.91 -0.04
Total Assets 4,961.9 163.6
Return on Equity % -12.31 -72.9
Return on Assets % -3.64 -56
Cash+ ST Inv. Per Share 8.51 1.41
Total Debt 2,679.7 23.8
Total Debt to Equity % 182.88 18.89
Total Debt to Tangible Equity % n/a 18.89
Debt to Asset % 54.01 14.51

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Dermatology  
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Hydroxyzine Pamoate
  
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.

Buyer Products:

  • Pliva Cyproheptadine HCl
  
Ophthalmology  
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.

Buyer Products:

  • Pliva Cyproheptadine HCl
  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventingcyclooxygenase activity.

Buyer Products:

  • Pliva Ketorolac Tromethamine
  
Systemic  
Anaphylactic Shock  
Adjunctive Treatments  
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.

Buyer Products:

  • Pliva Cyproheptadine HCl
  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.

Buyer Products:

  • Pliva Cyproheptadine HCl
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Fexofenadine/Pseudoephedrine
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Triamcinolone Acetonide Nasal Spray
  
Cardiovascular System
Heart Disorders  
Angina  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Pliva Propranolol Hydrochloride
  
Arrhythmia  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Pliva Propranolol Hydrochloride
  
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Buyer Products:

  • Flecainide Acetate
  • Pliva Propafenone HCl
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Buyer Products:

  • Amiodarone Hydrochloride
  
Heart Failure (HF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.

Buyer Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.

Buyer Products:

  • Pliva Chlorthalidone
  
Myocardial Infarction (MI)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Pliva Propranolol Hydrochloride
  
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • rNAPc2 (Recombinant Nematode Anticoagulant Protein c2)
  
Vascular Disorders  
Aneurysms  
Hemorrhage  
Calcium Channel Blocking Agents
Therapeutics that treat bleeding from aneurysms by blocking the flow of calcium ions from the blood vessel wall.

Buyer Products:

  • Nimodipine
  
Atherosclerosis  
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niaspan (Niacin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Buyer Products:

  • Warfarin Sodium
  
Hypertension  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.

Buyer Products:

  • Pliva Doxazosin Mesylate
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Duramed Zebeta (Bisoprolol Fumarate)
  • Pliva Propranolol Hydrochloride
  
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Pliva Propranolol Hydrochloride/Hydrochlorothiazide
  • Duramed Ziac (Bisoprolol Fumarate/Hydrochlorothiazide)
  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  • Amiloride Hydrochloride/Hydrochlorothiazide
  
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.

Buyer Products:

  • Pliva Chlorthalidone
  
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.

Buyer Products:

  • Pliva Hydralazine
  
Peripheral Vascular Disease  
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.

Buyer Products:

  • Pliva Pentoxifylline
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.

Buyer Products:

  • Dipyridamole
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Warfarin Sodium
  
Tremors  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.

Buyer Products:

  • Pliva Propranolol Hydrochloride
  
Dermatology  
Acne  
Vulgaris  
Antibacterial Agents  
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Erythromycin
  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Tetracycline Hydrochloride
  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Buyer Products:

  • Claravis (Isotretinoin)
  
Lesion/Scaling Disorders  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Buyer Products:

  • Fexofenadine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  
Pruritus  
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Hydroxyzine Pamoate
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.

Buyer Products:

  • Pliva Cyclosporine
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroduodenal Disorders  
Peptic Ulcers  
Duodenal  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pliva Cimetidine
  
Gastric  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pliva Cimetidine
  
Gastroesophageal Disorders  
Acid Indigestion/Heartburn  
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.

Buyer Products:

  • Pliva Cimetidine
  
Gastroesophageal Reflux Disease (GERD)  
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.

Buyer Products:

  • Pliva Metoclopramide Hydrochloride
  
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pliva Cimetidine
  
Gastroparesis  
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.

Buyer Products:

  • Pliva Metoclopramide Hydrochloride
  
Nausea/Vomiting  
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Pliva Hydroxyzine Hydrochloride
  
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.

Buyer Products:

  • Pliva Metoclopramide Hydrochloride
  • Prochlorperazine Maleate
  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Ondansetron Hydrochloride
  • Granisetron Hydrochloride
  
Intestinal Disorders  
Intestinal Intubation  
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.

Buyer Products:

  • Pliva Metoclopramide Hydrochloride
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Endocrinology/Metabolism  
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Buyer Products:

  • Fludrocortisone Acetate
  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Buyer Products:

  • Desmopressin Acetate
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Buyer Products:

  • Metformin Hydrochloride Extended-Release
  • Metformin Hydrochloride
  
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.

Buyer Products:

  • Metformin Hydrochloride/Glipizide
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • Acetohexamide
  • Pliva Chlorpropamide
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Buyer Products:

  • Estradiol
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.

Buyer Products:

  • Methylprednisolone
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Buyer Products:

  • Sulfinpyrazone
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.

Buyer Products:

  • Sulfinpyrazone
  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Reproductive Disorders  
Amenorrhea  
Progestins
Female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Medroxyprogesterone
  • Duramed Aygestin (Norethindrone Acetate)
  
Menopause  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Progestins
Therapeutics that are female sex hormones.

Buyer Products:

  • Medroxyprogesterone
  
Hematology  
Hemophilia  
Hemophilia A  
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.

Buyer Products:

  • Desmopressin Acetate
  
Red Blood Cell (RBC) Disorders  
Anemia  
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.

Buyer Products:

  • Leucovorin
  
Serum Factor Disorders  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Buyer Products:

  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Advicor (Niacin/Lovastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.

Buyer Products:

  • Sulfinpyrazone
  
Hypokalemia  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Thrombocyte (Platelet) Disorders  
Thrombocythemia  
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.

Buyer Products:

  • Anagrelide Hydrochloride
  
Immunology  
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Pliva Salsalate
  • Pliva Diclofenac Sodium
  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Leflunomide
  
Immunotherapy  
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.

Buyer Products:

  • Pliva Cyclosporine
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.

Buyer Products:

  • Pliva Cyclosporine
  
Immune Deficiency Disorders  
Hereditary Angioedema  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Buyer Products:

  • Danazol
  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Didanosine Delayed Release
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Pliva Azithromycin I.V.
  • Erythromycin
  
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.

Buyer Products:

  • Pliva Metronidazole
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Buyer Products:

  • Tetracycline Hydrochloride
  • Demeclocycline Hydrochloride
  
Narrow Spectrum  
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.

Buyer Products:

  • Erythromycin Ethylsuccinate/Sulfisoxazole
  
Respiratory System  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Ethambutol Hydrochloride
  • Isoniazid
  
Systemic  
Leprosy  
Erythema Nodosum Leprosum (ENL)  
Immunomodulatory Agents
Therapeutics that treat a bacterial infection characterized by the formation of tender, red nodules on the front of the legs by stimulating the immune system.

Buyer Products:

  • Thalidomide
  
Urology  
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Azoles  
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Pliva Ketoconazole
  
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Narrow Spectrum  
Dermatology  
Candidiasis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.

Buyer Products:

  • Pliva Nystatin
  
Digestive System  
Mucous  
Candidiasis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.

Buyer Products:

  • Pliva Nystatin
  
Nervous System  
Cryptococcal Meningitis  
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Pliva Fluconazole
  
Otolaryngology (Ear/Nose/Throat)  
Esophageal Candidiasis  
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Pliva Fluconazole
  
Oropharyngeal Candidiasis  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Pliva Fluconazole
  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.

Buyer Products:

  • Pliva Nystatin
  
Urology  
Vaginal Candidiasis  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Pliva Fluconazole
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • Adenovirus Vaccine
  
Protozoal  
Antiprotozoal Agents  
Broad Spectrum  
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.

Buyer Products:

  • Pliva Metronidazole
  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Buyer Products:

  • Mefloquine Hydrochloride
  
Viral  
RNA Viruses  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Didanosine Delayed Release
  
Musculoskeletal System  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Hormonal Treatments  
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Estradiol
  • Estropipate
  
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
  
Joint Disorders  
Ankylosing Spondylitis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Pliva Diclofenac Sodium
  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Buyer Products:

  • Sulfinpyrazone
  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Pliva Salsalate
  • Pliva Diclofenac Sodium
  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Pliva Salsalate
  • Pliva Diclofenac Sodium
  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Leflunomide
  
Immunotherapy  
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.

Buyer Products:

  • Pliva Cyclosporine
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.

Buyer Products:

  • Galantamine Hydrobromide
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Topiramate
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Topiramate
  • Zonisamide
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Topiramate
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  • Pliva Valproic Acid
  
Monotherapy  
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.

Buyer Products:

  • Pliva Ethosuximide
  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Pliva Valproic Acid
  • Clonazepam ODT
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Clonazepam ODT
  
Tonic-Clonic (Grand Mal)  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Topiramate
  
Headaches  
Tension Type  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Buyer Products:

  • Isometheptene/Dichloralphenazone/Acetaminophen
  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  
Vascular (Migraine)  
Acute Treatments  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Buyer Products:

  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  • Isometheptene/Dichloralphenazone/Acetaminophen
  
Prophylactic Treatments  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.

Buyer Products:

  • Pliva Propranolol Hydrochloride
  
Neuromuscular Disorders  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Buyer Products:

  • Pyridostigmine Bromide
  
Parkinson`s Disease (PD)  
Adjunctive Treatments  
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.

Buyer Products:

  • Pliva Benztropine Mesylate
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.

Buyer Products:

  • Pliva Hydroxyzine Hydrochloride
  • Hydroxyzine Pamoate
  
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.

Buyer Products:

  • Prochlorperazine Maleate
  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Alprazolam Extended Release
  • Chlordiazepoxide Hydrochloride
  • Diazepam
  
Obsessive Compulsive Disorder (OCD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.

Buyer Products:

  • Pliva Sertraline Hydrochloride
  • Fluvoxamine Maleate
  • Fluoxetine Hydrochloride
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Alprazolam Extended Release
  • Clonazepam ODT
  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Pliva Sertraline Hydrochloride
  
Post-Traumatic Stress Disorder (PTSD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Pliva Sertraline Hydrochloride
  
Social Anxiety Disorder (SAD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Pliva Sertraline Hydrochloride
  
Childhood/Adolescent Disorders  
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.

Buyer Products:

  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets
  • Dextroamphetamine Sulfate Extended Release
  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Buyer Products:

  • Desmopressin Acetate
  
Eating Disorders  
Bulimia  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.

Buyer Products:

  • Fluoxetine Hydrochloride
  
Mood Disorders  
Bipolar Disorders (Manic Depressive Disorders)  
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.

Buyer Products:

  • Lithium Carbonate Extended Release
  
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Olanzapine
  • Risperidone
  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Buyer Products:

  • Trazodone Hydrochloride
  • Pliva Sertraline Hydrochloride
  • Fluoxetine Hydrochloride
  
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.

Buyer Products:

  • Mirtazapine
  
Premenstrual Dysphoric Disorders  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.

Buyer Products:

  • Pliva Sertraline Hydrochloride
  
Schizophrenia  
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.

Buyer Products:

  • Prochlorperazine Maleate
  
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Olanzapine
  • Risperidone
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Zolpidem Extended Release
  • Diazepam
  
Narcolepsy  
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.

Buyer Products:

  • Modafinil
  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.

Buyer Products:

  • Dextroamphetamine Sulfate Extended Release
  
Obstetrics/Gynecology  
Child Birth/Pregnancy  
Prevention (Contraception)  
Contraceptives (Birth Control)  
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Kelnor (Ethynodiol Diacetate/Ethinyl Estradiol)
  
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Velivet (Desogestrel/Ethinyl Estradiol)
  • Portia (Levonorgestrel/Ethinyl Estradiol)
  • Enpresse (Levonorgestrel/Ethinyl Estradiol)
  • Kariva (Desogestrel/Ethinyl Estradiol)
  • Lessina (Levonorgestrel/Ethinyl Estradiol)
  • Nortrel (Ethinyl Estradiol/Norethindrone) 7/7/7
  • Duramed Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Sprintec/Tri-Sprintec (Norgestimate/Ethinyl Estradiol)
  • Aviane 28 (Levonorgestrel/Ethinyl Estradiol)
  • Cryselle (Norgestrel/Ethinyl Estradiol)
  • Duramed Nordette Tablets (Levonorgestrel/Ethinyl Estradiol)
  • Seasonique Extended Release (Levonorgestrel/Ethinyl Estradiol)
  • Loestrin Fe (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Junel (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Drospirenone/Ethinyl Estradiol
  • Lo Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Aranelle (Norethindrone/Ethinyl Estradiol)
  • Mircette (Desogestrel Ethinyl Estradiol)
  • Apri (Desogestrel/Ethinyl Estradiol)
  
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system

Buyer Products:

  • Errin (Norethindrone)
  • Plan B Prescription (Levonorgestrel)
  • Norethindrone Acetate
  • Camila (Norethindrone)
  • Plan B OTC (Levonorgestrel)
  
Female Genital Disorders  
Endometriosis  
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danazol
  
Ovarian  
Hypogonadism  
Hormonal Treatments  
Estrogens
These are female sex hormones.

Buyer Products:

  • Estradiol
  • Estropipate
  
Vulvovaginal  
Atrophy  
Hormonal Treatments  
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Buyer Products:

  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Bijuva Cream (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.

Buyer Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  
Oncology
Breast Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Buyer Products:

  • Tamoxifen Citrate
  
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.

Buyer Products:

  • Megestrol Acetate
  
Metastatic  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Buyer Products:

  • Tamoxifen Citrate
  
Dermatology  
Malignant Melanoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Buyer Products:

  • Leucovorin
  
Head/Neck Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Lymphoid  
Acute  
Lymphocytic  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Meningeal  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.

Buyer Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Myeloid  
Chronic  
Myelogenous (CML)  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Lymphoma (Lymphatic Cancer)  
Non-Hodgkin`s Lymphoma (NHL)  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.

Buyer Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Multiple Myeloma (Plasma Cell Cancer)  
Immunomodulatory Agents
Therapeutics that treat multiple myeloma by stimulating the immune system.

Buyer Products:

  • Thalidomide
  
Musculoskeletal System  
Bone Cancer  
Osteosarcoma  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Buyer Products:

  • Leucovorin
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • rNAPc2 (Recombinant Nematode Anticoagulant Protein c2)
  • Provenge (Sipuleucel-T)
  • Neuvenge (Lapuleucel-T)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Target Products:

  • Serine Protease Inhibitors
  • Trp-p8 Monoclonal Antibodies
  • CA-9 (Carbonic Anhydrase 9 Antigen)
  • Carcinoembryonic Antigen (CEA) Vaccine
  • Trp-p8 Vaccine
  • rNAPc2 (Recombinant Nematode Anticoagulant Protein c2)
  • Trp-p8 Small Molecule
  
Urology
Endometrial Cancer  
Localized  
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Megestrol Acetate
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Hormonal Treatments  
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.

Buyer Products:

  • Megestrol Acetate
  
Ovarian Cancer  
Adenocarcinoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.

Buyer Products:

  • Hydroxyurea
  
Prostate Cancer
Localized  
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.

Buyer Products:

  • CyPat (Cyproterone)
  
Metastatic
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Buyer Products:

  • Flutamide
  
Vaccines
Therapeutics that treat prostate cancers that have spread beyond the initial tumor by eliciting a specific immune response.

Target Products:

  • Provenge (Sipuleucel-T)
  
Ophthalmology  
Degenerative Disorders  
Glaucoma  
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Duramed Diamox (Acetazolamide)
  
Irritation/Inflammation  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Pliva Ketorolac Tromethamine
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Diazepam
  
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Acetaminophen/Codeine
  • Oxycodone/Acetaminophen
  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Meperidine Hydrochloride
  • Pliva Tramadol Hydrochloride
  • Oral Transmucosal Fentanyl Citrate [C-II]
  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Pliva Diclofenac Sodium
  • Pliva Naproxen Sodium
  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Buyer Products:

  • Chlorzoxazone
  • Pliva Cyclobenzaprine HCL
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Pliva Theophylline
  
Bronchitis  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Pliva Theophylline
  
Emphysema  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Buyer Products:

  • Pliva Theophylline
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.

Buyer Products:

  • Pliva Cyproheptadine HCl
  
Antitussives
Therapeutics that relieve or prevent coughs.

Buyer Products:

  • Pliva Benzonatate
  
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.

Buyer Products:

  • MedTuss HD Elixir C-III
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Triamcinolone Acetonide Nasal Spray
  
Surgery  
Cardiovascular System  
Thrombosis  
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Warfarin Sodium
  
General  
Complications  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.

Buyer Products:

  • Ondansetron Hydrochloride
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Warfarin Sodium
  
Ophthalmology  
Ocular Inflammation  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation resulting from surgical procedures to remove cataracts by preventing cyclooxygenase activity.

Buyer Products:

  • Pliva Ketorolac Tromethamine
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Buyer Products:

  • Chlordiazepoxide Hydrochloride
  • Diazepam
  
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.

Buyer Products:

  • Naltrexone Hydrochloride
  • Duramed ReVia (Naltrexone Hydrochloride)
  
Narcotics  
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.

Buyer Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Transplantation  
Heart  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • Pliva Cyclosporine
  
Hepatic (Liver)  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • Pliva Cyclosporine
  
Renal (Kidney)  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • Pliva Cyclosporine
  
Urology  
Male Genital Disorders  
Prostate  
Benign Prostate Hyperplasia (BPH)  
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.

Buyer Products:

  • Finasteride
  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.

Buyer Products:

  • Pliva Doxazosin Mesylate
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Oxybutynin TVR
  
Urological Disorders  
Bladder  
Neurogenic Bladder Disease  
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.

Buyer Products:

  • Pliva Oxybutynin Chloride
  
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.

Buyer Products:

  • Pliva Bethanechol Chloride
  
Urinary Frequency/Urge Incontinence  
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.

Buyer Products:

  • Pliva Oxybutynin Chloride
  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Buyer Products:

  • Triamterene/Hydrochlorothiazide
  
Weight Management  
Anorexia (Appetite Loss)  
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.

Buyer Products:

  • Megestrol Acetate
  
Cachexia  
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.

Buyer Products:

  • Oxandrolone
  
Progestins
Therapeutics that treat cachexia by providing female hormones.

Buyer Products:

  • Megestrol Acetate
  
Medical Devices  
General Surgery  
Invasive  
Transplantation  
Organ Preservation
Devices used to preserve organs prior to transplantation.

Buyer Products:

  • ViaSpan (Belzer UW)
  
Obstetrics/Gynecology  
Treatment  
Procedure Specific  
Contraception  
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.

Buyer Products:

  • ParaGard T 380A
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Johnson & Johnson n/a 186,667.352 18.09 15.92 3.37 3.09 n/a
Roche Holding Ltd. (ADR) n/a 167,078.347 25.55 21.45 4.79 4.07 7.17
Novartis AG (ADR) n/a 137,235.137 25.15 17.27 3.60 3.62 3.39
Wyeth n/a 76,653.715 17.70 16.19 3.67 3.47 n/a
Amgen, Inc. n/a 73,874.670 24.14 15.36 5.01 4.86 15.38
Eli Lilly & Co. n/a 67,520.389 28.90 17.50 4.17 3.80 7.40
Bristol Myers Squibb Co. n/a 59,076.989 37.84 20.81 3.34 2.96 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 23,176.573 12.22 18.50 2.63 2.57 17.09
Shire plc (ADR) n/a 12,959.832 39.30 35.44 6.77 5.78 6.67
Cephalon, Inc. n/a 5,274.820 36.42 20.38 2.99 3.00 107.09
Mylan Laboratories Inc. n/a 4,916.688 14.20 13.88 3.39 3.17 5.42
Warner Chilcott Ltd. n/a 4,151.882 n/a 17.84 5.50 4.94 n/a
Watson Pharmaceuticals, Inc. n/a 3,198.318 n/a 24.58 1.43 1.22 31.07
Dr. Reddy's Laboratories Limited (ADR) n/a 2,661.301 19.73 16.03 2.04 1.95 n/a
Target
  MannKind Corporation n/a 1,047.447 n/a -3.61 10,641.31 23.15 2.73
Pharmion Corporation n/a 1,001.473 n/a -18.99 4.09 3.93 n/a
GPC Biotech AG (ADR) n/a 987.374 n/a n/a 32.58 n/a 11.06
Cell Genesys, Inc. n/a 285.207 n/a -2.26 209.19 14.60 6.55
Cerus Corporation n/a 200.661 n/a -5.36 5.64 9.65 1.99
IDM Pharma Inc. n/a 160.524 n/a n/a 14.22 n/a 39.53
Cyclacel Pharmaceuticals Inc. n/a 159.179 n/a -4.83 411.11 104.09 3.11
Antigenics, Inc. n/a 138.098 n/a n/a 199.39 n/a n/a
Pro-Pharmaceuticals, Inc. n/a 33.503 n/a n/a n/a n/a n/a
AVAX Technologies, Inc. n/a 18.764 n/a n/a 22.14 n/a 12.54
Therion Biologics Corporation n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Mack-Cali Realty Corp. n/a 3,221.423 22.58 14.03 4.35 4.94 2.11
Indevus Pharmaceuticals n/a 551.419 n/a -9.66 10.09 7.77 n/a
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Akzo Nobel N.V. (ADR) n/a 22,972.082 13.88 16.37 1.25 1.52 5.06

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  McKesson Corporation 27.00% 17,723.820 20.23 20.92 0.19 0.19 4.17
Cardinal Health, Inc. 15.00% 28,320.872 20.98 20.85 0.33 0.32 8.18
AmerisourceBergen Corp. 11.00% 9,723.267 19.72 20.05 0.15 0.15 2.37
Walgreen Company 10.00% 44,705.141 22.75 21.52 0.88 0.82 4.23
Warner Chilcott Ltd. n/a 4,151.882 n/a 17.84 5.50 4.94 n/a
Indevus Pharmaceuticals n/a 551.419 n/a -9.66 10.09 7.77 n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a
Target
  Genentech, Inc. n/a 85,742.338 35.76 30.89 8.46 7.32 10.23
Amgen, Inc. n/a 73,874.670 24.14 15.36 5.01 4.86 15.38

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Akzo Nobel N.V. (ADR) n/a 22,972.082 13.88 16.37 1.25 1.52 5.06
Buyer
  Abbott Laboratories n/a 89,961.153 58.06 20.43 3.98 3.94 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 23,176.573 12.22 18.50 2.63 2.57 17.09
Akzo Nobel N.V. (ADR) n/a 22,972.082 13.88 16.37 1.25 1.52 5.06
Shire plc (ADR) n/a 12,959.832 39.30 35.44 6.77 5.78 6.67
Cephalon, Inc. n/a 5,274.820 36.42 20.38 2.99 3.00 107.09
King Pharmaceuticals, Inc. n/a 5,125.736 17.74 12.89 2.58 2.56 3.89
Warner Chilcott Ltd. n/a 4,151.882 n/a 17.84 5.50 4.94 n/a
Par Pharmaceutical Companies, Inc n/a 988.091 n/a 18.43 1.94 1.35 2.84
Savient Pharmaceuticals, Inc. n/a 633.871 10.51 -20.25 13.34 n/a 3.57
Indevus Pharmaceuticals n/a 551.419 n/a -9.66 10.09 7.77 n/a
Paladin Labs Inc. n/a 168.010 33.11 n/a 3.97 n/a 3.56
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Genentech, Inc. n/a 85,742.338 35.76 30.89 8.46 7.32 10.23
Amgen, Inc. n/a 73,874.670 24.14 15.36 5.01 4.86 15.38
Bayer AG (ADR) n/a 53,708.775 23.37 17.64 1.36 1.26 n/a
Akzo Nobel N.V. (ADR) n/a 22,972.082 13.88 16.37 1.25 1.52 5.06
Nuvelo, Inc. n/a 207.347 n/a -3.06 53.34 55.00 3.25
Mayo Foundation for Medical Education and Research n/a n/a n/a n/a n/a n/a n/a
The American Red Cross n/a n/a n/a n/a n/a n/a n/a
Progenitor Cell Therapy, LLC. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 1,450.7 0.3 1,450.9
Other Revenue 144.2 0.0 144.2
Total Revenue 1,594.9 0.3 1,595.2
Cost of Revenue 581.2 0.0 581.2
SG&A Expense 450.2 23.5 473.8
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 181.6 74.1 255.7
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 380.7 0.0 380.7
Total Expenses 1,593.7 97.6 1,691.4
Operating Income 1.2 -97.4 -96.2
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -7.0 4.3 -2.7
Other, Net -55.1 0.0 -55.1
Income Before Taxes -61.0 -91.6 -152.6
Income Taxes 119.5 0.0 119.5
Income After Taxes -180.4 -91.6 -272.1
Minority Interest (IS) 0.6 0.0 0.6
Net Income - Excl. Xord. Items -179.8 -91.6 -271.4
Net Income - Incl. Xord. Items -179.8 -91.6 -271.4
Income Avail. to Common -179.8 -91.6 -271.4
Share Items
Basic Avg. Shares Outstanding 106.4 75.8 182.2
Basic EPS - Excl. Xord. Items n/a n/a -1.49
Basic EPS - Incl. Xord. Items n/a n/a -1.49
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 106.4 75.8 182.2
F.D. EPS - Excl. Xord. Items n/a n/a -1.49
F.D. EPS - Incl. Xord. Items n/a n/a -1.49
Balance Sheet
Assets
Cash and Equivalents 232.0 61.0 292.9
ST Investments 673.8 45.5 719.3
Accounts Receivable 611.3 0.0 611.3
Inventory 452.4 0.0 452.4
Prepayments and Advances 36.0 0.0 36.0
Other Current Assets 82.6 3.5 86.1
Current Assets 2,088.0 110.0 2,198.0
PPE 1,207.0 46.5 1,253.5
Accum D&A -196.8 -15.9 -212.7
PPE, Net 1,010.2 30.5 1,040.7
Goodwill & Intangibles 1,750.6 0.0 1,750.6
Long Term Investments 8.9 14.8 23.8
Other Assets 0.0 0.0 0.0
Other LT Assets 104.1 8.3 112.4
Total Assets 4,961.9 163.6 5,125.5
Liabilities
Accounts Payable 156.1 1.5 157.6
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 283.7 10.9 294.6
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 742.4 6.7 749.2
Other (Current) Liabilities 29.6 1.3 30.9
Current Liab. 1,211.9 20.4 1,232.3
LT Debt 1,937.2 7.9 1,945.1
Capitalized Lease Obligations 0.0 9.1 9.1
Total LT Debt 1,937.2 17.0 1,954.2
Minority Interest (BS) 41.1 0.0 41.1
Deferred Taxes 221.9 0.0 221.9
Other LT Liab. 84.5 0.5 85.0
Total Liabilities 3,496.6 37.9 3,534.6
Shareholders Equity
Common Stock 1.1 0.1 1.2
Additional Paid in Capital 610.2 518.1 1,128.4
Retained Earnings 878.0 -392.4 485.6
Treasure Stock -100.7 0.0 -100.7
Other Equity 76.6 -0.1 76.5
Total Equity 1,465.2 125.7 1,590.9
Total Liab. & Equity 4,961.9 163.6 5,125.5
Shares Outstanding 106.6 81.3 187.9
Cash Flow
Operating Cash Flow
CF Net Income -179.8 -91.6 -271.4
CF Depreciation 110.9 3.9 114.8
CF Deferred Taxes -28.8 0.0 -28.8
Other Non-Cash Items 456.5 5.7 462.2
Change in Working Capital 77.1 1.1 78.2
Total Cash From Operating Activities 435.9 -81.0 355.0
Investing Cash Flow (not calculated)
Capital Expenditures -58.6 -12.5 -71.1
Other Investing Cash Flows -2,612.1 24.4 -2,587.7
Total Cash From Investing Activities -2,670.7 11.9 -2,658.8
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 36.0 42.4 78.3
Purchase and Retirement of Debt 2,409.9 -5.2 2,404.7
Other Financing Cash Flow -8.6 10.9 2.4
Total Cash From Financing Activities 2,437.3 48.1 2,485.4
Exchange Rate Effects -0.6 0.0 -0.6
Net Change in Cash 202.0 -21.0 181.0
Cash Taxes Paid 104.4 0.0 104.4
Cash Interest Paid 6.5 1.8 8.3